Phase 2 study of CMB305 in patients with tumours

Trial Profile

Phase 2 study of CMB305 in patients with tumours

Planning
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2015

At a glance

  • Drugs CMB 305 (Primary)
  • Indications Cancer
  • Focus Therapeutic Use
  • Sponsors Immune Design
  • Most Recent Events

    • 31 Mar 2015 According to a company media release, Immune Design plans to commence this expansion study at the optimal dose in patients with any of four tumor types: sarcoma, lung, ovarian and melanoma.
    • 17 Dec 2014 New trial record
    • 13 Nov 2014 According to an Immune Design media release, this is one of the two phase 2 studies and it is intended to begin in the later part of 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top